| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K50799972 | CTRPv2 | pan-cancer | AAC | 0.096 | 0.008 |
| mRNA | BRD-K44224150 | CTRPv2 | pan-cancer | AAC | 0.19 | 0.01 |
| mRNA | elocalcitol | CTRPv2 | pan-cancer | AAC | 0.08 | 0.02 |
| mRNA | BRD-K34099515 | CTRPv2 | pan-cancer | AAC | 0.17 | 0.02 |
| mRNA | BRD-K55116708 | CTRPv2 | pan-cancer | AAC | 0.084 | 0.02 |
| mRNA | BRD-K16147474 | CTRPv2 | pan-cancer | AAC | 0.09 | 0.02 |
| mRNA | BRD-K80183349 | CTRPv2 | pan-cancer | AAC | 0.074 | 0.02 |
| mRNA | BMS-195614 | CTRPv2 | pan-cancer | AAC | 0.086 | 0.02 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.084 | 0.02 |
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | 0.17 | 0.02 |